Navigation Links
Lexicon Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
Date:3/29/2011

THE WOODLANDS, Texas, March 29, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the 10th Annual Needham Healthcare Conference on Wednesday, April 6, 2011 at 2:40 p.m. Eastern Time in New York City.  Dr. Sands will provide an overview on Lexicon's clinical development programs and milestones.

A live webcast of the presentation will be available through Lexicon's corporate website at www.lexpharma.com.  An archived version of the presentation will be available for 30 days after the event.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
2. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
3. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
4. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
5. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
6. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
10. Lexicon Announces Pricing of Common Stock in Public Offering
11. Lexicon to Present at Two Major Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Recent ... cell type. Many treatments for specific cancers, such as breast, prostate, or lung, ... is androgen deprivation therapy for advanced prostate cancer. , This therapy limits ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar ... has secured $2M in funding from an impressive group of investors, including Rev1 ... Thrive Fund. With this investment, 3Bar is broadening availability of its groundbreaking offering ...
(Date:8/16/2017)... edition of the Inc. 5000 features a now-familiar name: BioPoint ( http://biopointinc.com/ ... list for the third year in a row. Now in its 36th ... a set of quantitative metrics. In addition, BioPoint was also named to ... Bay State . ... ...
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past ... support with crowdsourced data collection, GeneFo now offers this platform to ... aligning and amplifying support, adherence, and data collection vis a vis ... foundations mark the successful launch of this offer. ... GeneFo ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):